Zach Klaassen· @zklaassen_md · X·· 2 天前评分70
正文 · 原文
Capi + Abi vs PBO + Abi in PTEN-deficient mHSPC: Updated OS from CAPItello-281 @urotoday #ESMO26
Capi + Abi vs PBO + Abi:
📌mOS: 57.4 mos vs 46.5 mos; HR 0.82, 95%CI 0.68–0.99; p=0.044
📌m-rPFS: 35.5 mos vs 26.0 mos; HR 0.83, 95%CI 0.70–0.99; p=0.033
📌mSSE-FS: 43.8 mos vs 35.9 mos; HR 0.83, 95%CI 0.69–0.99; p=0.044
178 浏览 · 2 赞 · 0 转发 · 0 回复
会议摘要
Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281
https://esmocongress.esmo.org来源：Zach Klaassen · x.com